Therapeutics and mild cognitive impairment: current status and future directions.
Thal
Leon J
LJ
Department of Neuroscience, University of California, San Diego School of Medicine, La Jolla, California 92093, USA. lthal@ucsd.edu
D000544:Alzheimer Disease / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D018680:Cholinergic Antagonists / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D002986:Clinical Trials as Topic; D000077265:Donepezil; D004967:Estrogens / Q000494:pharmacology; D006801:Humans; D007189:Indans / Q000494:pharmacology; D007249:Inflammation; D010880:Piperidines / Q000494:pharmacology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014810:Vitamin E / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D004967:Estrogens; D007189:Indans; D010880:Piperidines; D014810:Vitamin E; D000077265:Donepezil